This webinar introduces a new technology OriGene develops for the validation of antibody specificity. Non-specific antibodies recognize "off-targets" in addition to their intended targets, which could generate false-positive results. This new tool, High-density Protein Microarray, has been used to test the specificity of commercial diagnostic antibodies and found some are not specific to their targets. This tool is also applied to identify the ultra-specific antibodies UltraMABs.
Views: 2538 OriGene Technologies Inc.